Scientists Discover How Lung Cancer Cells Change Identity to Escape Treatment
27 May 2026

Scientists Discover How Lung Cancer Cells Change Identity to Escape Treatment

Researchers at University of Southampton have uncovered a key mechanism that allows lung cancer cells to become more aggressive and resistant to treatment by switching back to an earlier developmental state.
Scientists Discover New Way to Make Immunotherapy More Effective in Breast Cancer
27 May 2026
Scientists Discover New Way to Make Immunotherapy More Effective in Breast Cancer
Researchers from Medical University of Vienna have identified a major mechanism that allows breast cancer tumours to escape the body’s immune system, opening the door for more effective immunotherapy treatments in the future.
AstraZeneca’s Breast Cancer Drug Camizestrant faces US FDA Delay as Agency Seeks More Clinical Data
27 May 2026
AstraZeneca’s Breast Cancer Drug Camizestrant faces US FDA Delay as Agency Seeks More Clinical Data
Pharma major AstraZeneca has received an extension in the US FDA review timeline for its investigational breast cancer therapy camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) being evaluated for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.
AstraZeneca-Daiichi’s Datroway Wins US Approval for Aggressive Breast Cancer
27 May 2026
AstraZeneca-Daiichi’s Datroway Wins US Approval for Aggressive Breast Cancer

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved DATROWAY (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval makes DATROWAY the first TROP2-directed antibody-drug conjugate (ADC) approved in the United States for first-line treatment in this patient population.

Research Career for Pharma, Biotechnology, Life Sciences at NIPER
26 May 2026
Research Career for Pharma, Biotechnology, Life Sciences at NIPER
First class post-graduate degree such as M.S. (Pharm)/ M.Pharm / MSc / M.Tech or Equivalent (with specialization in Pharmaceutics/ Pharmacology & Toxicology / Biotechnology/ Life Sciences
NITS-FIIE invites applications from Pharmacy and Science Graduates
26 May 2026
NITS-FIIE invites applications from Pharmacy and Science Graduates
Bachelors degree or higher in Engineering / Technology / Pharmacy from a recognized University / Institute.
Advertisement for Professor, Associate Professor, Assistant Professor at CIPT & AHS
26 May 2026
Advertisement for Professor, Associate Professor, Assistant Professor at CIPT & AHS
Faculty who can successfully execute R&D and consultancy will be considered. Faculty who can promote patents, Industry Interaction, and other value-added courses will be preferred.
Pharma Jobs for prospective cohort study at AIIMS
26 May 2026
Pharma Jobs for prospective cohort study at AIIMS
PhD, MD, MS, MDS or equivalent degree or having 3 years of research, teaching, design and development experience after MVSc/M.Pharm, ME, M.Tech with at least one research paper in Science Citation Indexed or PubMed Indexed journal.
Life Sciences Recruitment in Project funded by NII Core Grant
26 May 2026
Life Sciences Recruitment in Project funded by NII Core Grant
First Class Masters degree in any branch of Life Sciences from a recognised university / Institution.
PHARMACY PLACEMENT DRIVE Organized By Pharmacy Council of India
26 May 2026
PHARMACY PLACEMENT DRIVE Organized By Pharmacy Council of India

The Pharmacy Council of India (PCI) and Gujarat State Pharmacy Council (GSPC) In association with Pharmacy institutions of Gujarat state is organizing a placement drive for Pharmacy students.

PHARMACY PLACEMENT DRIVE

Eligible Participants
B.Pharm
M.Pharm (All Specializations)
Pharm.D
D.Pharm